Critical Bleeding with Severe Thrombocytopenia
Stabilize hemorrhage while distinguishing immune destruction, consumption and microangiopathy.
Stabilize hemorrhage while distinguishing immune destruction, consumption and microangiopathy.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.
Actionable Clinical Workflows (3)
Step-by-step ICU ProcessesFrom emergent massive-hemorrhage protocol activation and early balanced component resuscitation to physiologic correction, targeted factor/anticoagulant reversal, and definitive source control.
From assessing hemodynamic stability to correcting reversible contributors to coagulopathy.
Urgent maternal stabilization, left uterine displacement, syndromic differentiation, and multidisciplinary escalation.
Deep-Dive Topic Destinations (4)
Reference KnowledgeICU approach to isolated immune thrombocytopenia, bleeding severity, IVIG/steroids, platelet transfusion in critical bleeding, and rescue therapy.
Recognition of thrombotic microangiopathy, PLASMIC risk, ADAMTS13 testing, immediate plasma exchange, steroids, caplacizumab, and ICU complications.
Tissue-factor-driven coagulation activation, antithrombin/protein C depletion, PAI-1-associated fibrinolytic suppression, ISTH 2025 DIC assessment, comparison with TTP/HUS/HIT, and targeted replacement.
Patient-specific RBC transfusion thresholds, current platelet/procedural thresholds, plasma/cryoprecipitate use, and the TRALI vs TACO diagnostic matrix.